Skip to main content
H

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Filings indexed 1,824 across all filing types
Latest filing 2025-12-24 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司董事会提名委员会工作细则(2025年12月)
Regulatory Filings
2025-12-24 Chinese
哈药集团股份有限公司章程(2025年12月)
Regulatory Filings
2025-12-24 Chinese
哈药集团股份有限公司独立董事制度(2025年12月)
Regulatory Filings
2025-12-24 Chinese
哈药集团股份有限公司董事会议事规则(2025年12月)
Regulatory Filings
2025-12-24 Chinese
哈药集团股份有限公司关于修订《公司章程》的公告
Regulatory Filings
2025-12-24 Chinese
哈药集团股份有限公司关于控股股东部分股份解除质押的公告
Regulatory Filings
2025-11-19 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.